Posted by Michael Wonder on 25 Feb 2021
Humira (adalimumab) receives FDA approval to treat paediatric patients living with moderately to severely active ulcerative colitis
24 February 2021 - Humira (adalimumab) is the first and only subcutaneous biologic treatment option for paediatric patients from 5 years of age with moderately to severely active ulcerative colitis.
AbbVie today announced that the U.S. FDA approved Humira (adalimumab) for the treatment of moderately to severely active ulcerative colitis in paediatric patients 5 years of age and older.
In clinical trials, Humira induced clinical remission at Week 8 and maintained remission at Week 52 in patients who responded at Week 8.
